



DIASORIN LAUNCHES VZV DIRECT MOLECULAR TEST IN THE UNITED STATES

May 29, 2019 – DiaSorin (FTSE MIB: DIA) announced to have received FDA clearance for its new VZV Direct assay for use with cerebrospinal fluid (CSF) samples. The new molecular diagnostic test enables the detection of varicella-zoster virus (VZV) DNA from CSF and serves as an effective tool to aid in the diagnosis of meningitis and encephalitis.

VZV causes varicella, a highly communicable disease that is usually contracted in early childhood, but is also known to be the cause of some types of acute aseptic meningitis. After initial infection, VZV becomes latent in sensory nerve ganglia. Reactivation of the latent virus can occur with increased age or immunosuppression and causes herpes zoster (shingles), a painful condition associated with complications including post-herpetic neuralgia and central nervous system infections such as encephalitis.

It is estimated that greater than 90 percent of the population will acquire VZV by the age of 15 and each of these persons is at risk for developing encephalitis. The two most prevalent human herpesviruses identified in encephalitis setting are Herpes Simplex Virus (HSV) 1 and VZV, which commonly occur in middle age adults.

“HSV 1, HSV 2 and VZV on cerebrospinal fluid are part of the diagnostic algorithm for encephalitis in adults,” said Michelle Tabb, Chief Scientific Officer at DiaSorin Molecular LLC. *“Our new VZV Direct assay, together with our HSV 1 & 2 Direct assay provides physicians the answers they require in a timely manner for patient management.”*

DiaSorin

Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 50 years, the Company has been developing, producing and marketing reagent kits for IVD worldwide. The Group has a presence on the 5 continents with 25 companies, 5 foreign branches, 6 manufacturing facilities and 5 research centers throughout the world. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the “Diagnostic Specialist”.

For additional information, please contact:

Riccardo Fava
Corporate Vice President Communication & Investor Relations
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Ines Di Terlizzi
Investor Relator
Tel: +39.0161.487567
ines.diterlizzi@diasorin.it